Qiagen N.V. reaffirmed earnings guidance for the year 2024. For the year, the company has reaffirmed its outlook for net sales of at least $2.0 billion CER.
Market Closed -
Other stock markets
|
Pre-market 09:17:57 am | |||
45.99 USD | +0.48% | 45.82 | -0.38% |
May. 15 | Qiagen's Updated Clinical Decision Support Platform Secures EU Certification | MT |
May. 14 | QIAGEN Receives European IVDR Certification for QIAGEN Clinical Insight Interpret | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.72% | 10.2B | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.11% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- QGEN Stock
- News Qiagen N.V.
- Qiagen N.V. Reaffirms Earnings Guidance for the Year 2024